Loading...

AKTX AKARI THERAPEUTICS PLC Management Changes 8-K Filing

KR T

KTX

AKARI THERAPEUTICS PLC

(AKTX)

2025 8-K

Ratio Change Announcement

Shareholder Meeting Outcomes

Equity Financing Completed

Shareholder Meeting Results

Investor Presentation

Delisting Notification

Management Change

Securities Offering

Funding Announcement

Notes Offering Closed

Financial Amendments

Share Purchase Agreement

Promissory Notes Issued

Investor Presentation Update

Equity Offerings

Financial Statements

Financial Results

CEO Appointment

Securities Offering

Corporate Update

Management Changes

Management Change

Management Changes

Merger Completion

Merger Approval

Delisting Notice

Merger Agreement

Financial Results

Annual General Meeting

Appointment of Interim Pres...

Private Placement

Financial Results Announcement

Restructuring and reorganis...

Management Changes

Financial Results Announcement

Private Placement Agreement

Merger Agreement

Private Placement

External Links:

On October 22, 2025, Akari Therapeutics appointed Kameel Farag as interim Chief Financial Officer, succeeding Torsten Hombeck. Mr. Farag will receive a monthly fee of $18,000 plus $12,000 in RSUs, increasing to $27,000 plus $13,000 starting January 2026.

AI Assistant

AKARI THERAPEUTICS PLC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.